HIV/AIDS Clinical Trial
Official title:
Bridges2Scale: Testing Implementation Strategies for an Economic Empowerment Intervention Among Young People Orphaned by AIDS
The goal of this clinical trial is to compare two multifaceted strategies (standard vs enhanced) for scaling Bridges in a two-arm Hybrid III effectiveness-implementation cluster randomized controlled trial (RCT) in adolescent and youths affected by AIDS [AYaAIDS] (ages 13-17 years) from 48 schools in the Greater Masaka region of Uganda. The main aims of the clinical trial are: Aim 1. Compare the implementation effectiveness of the standard implementation strategy vs. an enhanced implementation strategy. The investigators will assess fidelity to Bridges (primary implementation outcome) and sustainment of Bridges (exploratory implementation outcome). Aim 2. Determine the clinical effectiveness of Bridges implemented via a standard vs. enhanced implementation strategy. Aim 3: Explore implementation processes, mechanisms, and determinants. Aim 4. Compare the cost and cost-effectiveness of the two implementation strategies. Using an activity-based ingredients approach, the investigators will examine how much each strategy costs to achieve a unit of effect.
Status | Recruiting |
Enrollment | 1440 |
Est. completion date | July 31, 2028 |
Est. primary completion date | March 31, 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 13 Years to 17 Years |
Eligibility | Inclusion Criteria: Adolescent inclusion criteria: 1. Ages 13-17 2. a student at one of the 48 public primary schools included in the study-schools located in high HIV/AIDS prevalence areas in the greater Masaka region 3. living within a family and not an institution/orphanage Caregiver inclusion criteria: 1. self-identified and confirmed by the adolescent and youth as primary caregiver of the adolescent and youth 2. capable of providing informed consent Youth-serving NGOs inclusion criteria: 1. registered with the government of Uganda 2. willing to work with the study team 3. have a history of implementing micro-finance economic empowerment interventions. Exclusion Criteria: 1. anyone with a significant cognitive impairment that interferes with their understanding of the informed consent process, or is unable/unwilling to consent. |
Country | Name | City | State |
---|---|---|---|
Uganda | International Center for Child Health and Development | Masaka |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intervention Fidelity | The proportion of research assistants/facilitators that achieve 85% agreement on at least 3 of the fidelity assessment checklists.
Field research assistants will be trained on using fidelity tools to track: (a) content of the intervention (e.g., saving), (b) process (e.g., mentoring skills), (c) activities (e.g., workshops). The team will practice fidelity assessment in pairs until they reach at least 85% agreement on at least 3 fidelity assessment checklists. In the field, independent fidelity observations will be conducted by research staff for 25% of Bridges sessions. Fidelity data will be used to assess the relationship between planned and actual implementation, and will be catalogued using FRAME-IS as a guide. |
Throughout intervention delivery (2 years (Baseline, 12 months, 24 months)) | |
Primary | HIV prevalence | Prevalence of adolescents positive for HIV among the sample determined from biomarker data | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) | |
Secondary | Sexual risk-taking behavior | Sexual risk-taking behavior will be measured using the Risk Behavior Survey. scores range from 0-20, with higher total scores indicating higher risk to engage in sexual risk behaviors. | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) | |
Secondary | Economic stability | Economic stability will be assessed via Bank statements | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) | |
Secondary | School attainment | School attainment will be assessed using the Adapted Monitoring the Future scale and the Primary Leaving Examinations (PLE) Results | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) | |
Secondary | Depressive Symptoms | Depressive symptoms was assessed using the Adapted Child Depression Inventory. The total score range between 0 and 28 with a high score indicating higher levels of depressive symptoms. | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) | |
Secondary | Proportion of adolescents living with HIV who are virally suppressed | Viral suppression will be assessed using biological assay | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) | |
Secondary | Proportion of HIV negative adolescents who use PrEP | PrEP use will be assessed using biological assay | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) | |
Secondary | Hopelessness | Hopelessness was assessed using the Beck Hopelessness Scale The total score range between 0 and 20 with a high score indicating higher levels of Hopelessness. | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) | |
Secondary | Self-Esteem | Self-esteem was assessed using the Rosenberg Self-Esteems Scale. Scale scores range from 0 to 30 with higher scores indicative of higher self-esteem. | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) | |
Secondary | Self-concept | Self-concept was assessed using the Tennessee Self-Concept Scale. Scale scores range from 20 to 100 with higher scores indicative of higher self-concept. | 4 years (Baseline, 12 months, 24 months, 36 months, 48 months post-baseline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT02376582 -
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
|
Phase 1 | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|